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Summary 14 
 15 
Background Elevated d-dimer levels are associated with poor clinical outcomes in subjects 16 
with treated HIV infection. Protease Activated Receptor-1 (PAR-1) is activated by thrombin 17 
and overexpressed on immune cells from HIV-infected subjects. We studied a licensed 18 
inhibitor of PAR-1, vorapaxar, to reduce HIV associated hypercoagulation and inflammation.  19 
 20 
Methods We performed a multicentre, double-blind, randomised, placebo-controlled trial 21 
involving HIV infected, aviremic participants on stable ART with d-dimer levels 22 
>200ng/mL. Outpatients in Australia and the USA were randomly assigned through 23 
computer generated block lists to receive vorapaxar (2·5mg orally daily), or matched 24 
placebo for 12 weeks. The primary endpoint was treatment group difference in changes 25 
from baseline d-dimer levels after 8–12 weeks of treatment in a modified intention-to-treat 26 
group. This trial is registered with Clinicaltrials.gov, number NCT02394730, and closed to 27 
new participants. 28 
 29 
Findings Between October 21 2015 and July 14 2017, 65 eligible subjects were randomly 30 
assigned to the placebo (n=31) or vorapaxar group (n=34). The modified intention to treat 31 
population comprised participants with at least one dose of study drug and/or one follow 32 
up visit (31 placebo, 33 vorapaxar). D-dimer levels after 8–12 weeks treatment were not 33 
different in vorapaxar compared to placebo treated groups (difference -0·02 log10ng/mL, 34 
95% CI of -0·10 to 0·05, p = 0·56). Vorapaxar treatment was safe and well tolerated in this 35 
subject cohort, with suppression of HIV replication maintained. 36 
 37 
Interpretation Vorapaxar had no impact on d-dimer levels or inflammatory markers in HIV 38 
infected subjects on stable ART but at risk for poor outcomes. Alternative approaches are 39 
needed to reduce hypercoagulation, inflammation and adverse long-term outcomes in 40 
subjects with treated HIV infection. 41 
 42 
Funding Australian National Health and Medical Research Council, U.S. National Cancer 43 
Institute, National Institutes of Health.  44 
 3 
Panel: Research in context  45 
 46 
Evidence before this study 47 
Cardiovascular disease is approximately 50% more common in HIV infected people despite 48 
ART. Standard cardiovascular risk factors remain important in the context of HIV infection. 49 
In addition, biomarkers in blood corresponding to increased coagulation and immune 50 
activation, particularly d-dimer, but also Interleukin-6 (IL-6) and high-sensitivity C-reactive 51 
protein (hs-CRP), appear to be important markers of HIV-related cardiovascular disease 52 
risk. It is not clear if the associated biomarker changes are causal or consequential. The 53 
physiological mechanisms underpinning poor clinical outcomes remain unclear. Vorapaxar is 54 
a novel oral anticoagulant recently licensed for secondary prevention of cardiovascular 55 
disease, which in HIV infection has potential to have an additional benefit through the 56 
reduction of immune activation. We searched PubMed for articles published between Jan 1 57 
2000 and July 1 2015 using “vorapaxar” and “HIV”, reporting a “study” or “trial”. We found 58 
no reports of vorapaxar in the context of HIV infection. 59 
 60 
Added value of this study 61 
To the best of our knowledge, this multicentre, double-blind, randomised, placebo-62 
controlled trial is the first to study vorapaxar in people with HIV infection at risk of future 63 
cardiovascular disease. This study found no effect of 12 weeks of treatment with vorapaxar 64 
on several biomarkers of cardiovascular risk, including no effect on d-dimer, IL-6, or hs-CRP 65 
levels.  66 
 67 
Implications of all the available evidence 68 
The results of our study suggest that vorapaxar should not be studied further as a treatment 69 
to reduce cardiovascular risk in people with HIV infection. Careful attention to existing 70 
proven interventions in HIV negative populations to modify cardiovascular disease risk 71 
remain the best available method to reduce cardiovascular disease in people with HIV 72 
infection.  73 
 4 
Introduction 74 
 75 
Elevated expression of d-dimer (a marker of coagulopathy) and elevated hs-CRP and IL-6 76 
(markers of immune activation/inflammation) are associated with increased risk of death 77 
and serious end-organ diseases among people with HIV infection.1–3 These markers are 78 
increased in untreated HIV replication, but even among people with well controlled HIV on 79 
combination antiretroviral therapy (ART) there is a consistent relationship between higher 80 
d-dimer levels and poorer clinical outcome.4–7 While ART reduces levels of d-dimer, it does 81 
not result in normalisation.6,8,9 Among subjects with suppressed plasma HIV RNA levels, 82 
expression of d-dimer and inflammation markers is higher than in age matched populations 83 
without HIV infection.10 Interventions to reduce either hypercoagulation and/or immune 84 
activation may both permit a clearer understanding of the underlying pathogenesis and be 85 
of therapeutic benefit. 86 
 87 
The relationship between coagulopathic disorder and immune activation is an evolving area 88 
of research interest.11–13 Tissue injury results in the release of tissue factor that promotes 89 
the coagulation cascade resulting in thrombus formation. T-cells differentially express 90 
receptors linked to this cascade and are activated at times when tissue injury has occurred.  91 
A novel observation suggests that CD8+ T lymphocytes from HIV infected persons over-92 
express Protease Activated Receptor-1 (PAR-1).14 PAR-1 is activated by thrombin and CD8+ 93 
cells expressing PAR-1 become activated (express cytokines and chemokines) in a dose 94 
dependent fashion to exogenous thrombin.  95 
 96 
The sources of tissue injury, immune activation and hypercoagulopathy in people with well 97 
controlled HIV replication are not known. Increased levels of tissue factor expression are 98 
present in monocytes from people with HIV-1 infection.15 Analysis of thrombin generation 99 
suggests the net effect of HIV replication is pro-coagulant, although the degree to which this 100 
persists after suppression of HIV replication is uncertain.16 It is plausible that tissue injury in 101 
the setting of HIV replication promotes thrombin formation and PAR-1 dependent signalling 102 
that in turn supports immune activation and inflammation.17 PAR-1 may therefore be a 103 
potential target for therapeutic manipulation in the setting of well controlled HIV infection. 104 
 105 
Vorapaxar is an oral competitive PAR-1 antagonist that mediates anticoagulation through 106 
inhibiting thrombin-induced platelet aggregation. Vorapaxar has been studied in large 107 
clinical endpoint trials in cardiovascular disease and is licensed as secondary prophylaxis for 108 
subjects with a history of myocardial infarction or peripheral arterial disease.18,19 We 109 
hypothesised that vorapaxar could reduce markers of hyper-coagulation and inflammation 110 
in subjects with well treated HIV at risk for adverse clinical outcomes.   111 
 5 
Methods 112 
 113 
Study design and participants 114 
The ADVICE study (Attenuation of D-dimer using Vorapaxar to target Inflammatory and 115 
Coagulation Endpoints) was a double-blind, randomised, placebo-controlled trial at seven 116 
health centres in 5 hospital clinic or general practice sites in Australia (Melbourne and 117 
Sydney) and 2 hospital clinic sites in the USA (Minneapolis and Washington DC). HIV 118 
infected people over the age of 40 with suppressed HIV viremia (plasma HIV RNA <50 copies 119 
per mL) for at least 24 weeks and a d-dimer level of >200ng/mL were eligible. Antiretroviral 120 
regimens excluded HIV protease and non-nucleoside reverse transcriptase inhibitors (except 121 
rilpivirine) because of potential drug-drug interactions with vorapaxar. Subjects taking other 122 
anti-coagulants or a history of cardiovascular disease were also excluded. A complete list of 123 
inclusion and exclusion criteria is provided in the trial protocol (Appendix page 12-111).  124 
 125 
The trial was approved by the research ethics board for each trial centre and was conducted 126 
in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice 127 
guidelines. All subjects provided written informed consent. The trial was monitored by an 128 
independent Data and Safety Monitoring Board (DSMB). The results were collected and 129 
analysed by the writing committee. No interim analysis was specified in the protocol nor 130 
recommended by the DSMB which reviewed safety data at predefined intervals or in 131 
response to reported serious adverse events.  132 
 133 
Randomisation and masking 134 
Randomisation was through computer generated block lists of size 2, stratified by site, and 135 
allocated double-blind through a web-based database system.  136 
 137 
Procedures 138 
Consenting participants were screened and within 14 days randomly allocated to receive 139 
either vorapaxar sulphate (2·5mg daily) or matched placebo for 12 weeks. Participants were 140 
reviewed and had a blood sample taken at weeks 1, 4, 8 and 12 during treatment. At the 141 
week 12 visit, the study treatment was stopped and subjects reviewed and had a blood 142 
sample taken at the week 18 final visit. 143 
 144 
Cryopreserved plasma samples were retrospectively batch-analysed at Leidos Biomedical 145 
Research Inc. (Maryland, USA) D-dimer was measured using an Enzyme Linked Flourescent 146 
Assay on a VIDAS instrument (bioMerieux, Marcy l'Etoile, France). Traditional ELISAs were 147 
used to measure sCD14 (R&D Systems, Minneapolis, MN, USA) and sCD163 (Aviscera 148 
Bioscience Inc., Santa Clara, CA, USA). Hs-CRP and IL-6 were measured by 149 
electrochemiluminescense (Meso Scale Discovery, Rockville, MD, USA).  150 
 151 
To measure PAR-1 levels, we used flow cytometry for PAR-1 expression on gated CD4 and 152 
CD8 T cells. This was performed on fresh blood (<4hr from venepuncture) in the subset of 153 
enrolled subjects in Australia (n=39) with access to validated flow cytometry assays. 154 
Detailed methods and gating strategies of the flow cytometry assays are shown in the 155 
Appendix page 5.   156 
 157 
All adverse events (see protocol in the Appendix page 12-111) were collected and 158 
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summarised by randomised treatment group, severity and relation to study drug.  Serious 159 
adverse events were summarised for all enrolled participants.  A particular focus of safety 160 
analyses was bleeding events given the anti-coagulant nature of vorapaxar and were 161 
classified according to the Bleeding Academic Research Consortium (BARC) criteria 162 
(Appendix page 12-111). 163 
 164 
Outcomes 165 
The primary endpoint was the difference between treatment groups in changes in d-dimer 166 
from baseline to the average of weeks 8 and week 12. Secondary endpoints included change 167 
in d-dimer between week 12 and week 18 (after cessation of vorapaxar/placebo), changes 168 
in HIV RNA, changes in CD4 and CD8 T cell counts, and changes in inflammatory markers hs-169 
CRP and IL-6. Pre-specified exploratory endpoints included changes in activation markers of 170 
monocytes (soluble CD14 and CD163) and PAR-1 expression on CD4 and CD8 T cells. Full 171 
details of all endpoints are provided in the protocol (Appendix page 12-111). Additional 172 
exploratory endpoints listed in the protocol of cell-associated HIV levels, ultrasensitive viral 173 
load, T cell activation markers and Natural Killer cell functions were not pursued. 174 
 175 
Statistical Analysis 176 
A linear regression for change (log10) of d-dimer from baseline to an average of weeks 8 177 
and 12 modelled against treatment and baseline outcome variable was used for the primary 178 
endpoint. The standard deviation of d-dimer levels in a previous study of ART-treated 179 
subjects with d-dimer >200ng/mL was 0·36 log10 ng/mL at week 12 and 0·41 log10 ng/mL at 180 
week 24.20 Using a repeated measures regression analysis at week 8 and 12, assuming 181 
variability in change in log10 d-dimer=0·4, and correlation between these two time points as 182 
0·57, then a total sample size of 56 subjects (28 in each arm) gives 80% power to detect a 183 
mean difference of 0·26 logs. Recruitment of 60 subjects was planned, allowing for some 184 
non-completion. To give an idea of the absolute magnitude of differences we would be 185 
powered to detect, assuming no change in log10 d-dimer in the placebo group, this mean 186 
difference of 0·26 logs corresponds to a 45% decrease in d-dimer from baseline in the 187 
vorapaxar group. This would move most subjects to at least one lower quartile of d-dimer 188 
levels. It has previously been calculated that a one quartile change in d-dimer levels is 189 
associated with an adjusted odds ratio of 5.3 for the risk of serious non-AIDS events 190 
(including cardiovascular events) or death.4 We reasoned that such a change in d-dimer, as a 191 
marker, would be required to justify pursuing vorapaxar in larger clinical studies. 192 
 193 
A detailed statistical analysis plan was prepared and finalised before the database was 194 
finalised (Appendix pages 112-117). A modified intention to treat approach was taken for 195 
primary analyses, including all randomised participants who received study drug and had 196 
any follow-up data. All available follow-up data were included regardless of whether 197 
participants ceased study drug. Changes in continuous endpoints were analysed using 198 
regression models adjusted for baseline values. Binary endpoints were analysed using 199 
logistic regression. All analyses were done with Stata (version 14.2). The study protocol was 200 
registered at clinicaltrials.gov (#NCT02394730). 201 
 202 
Role of the funding source 203 
The trial was designed by the authors and supported by funding from the Australian 204 
National Health and Medical Research Council and U.S. National Cancer Institute, National 205 
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Institutes of Health, which were not involved in the trial design, conduct, or analyses. The 206 
pharmaceutical company Merck provided vorapaxar and matched placebo but there was no 207 
other industry support or funding. Merck was not otherwise involved in the trial design, 208 
conduct, or analyses. The corresponding author had full access to all the data in the study 209 
and had final responsibility for the decision to submit for publication.  210 
 8 
Results 211 
A total of 125 participants underwent screening; 65 were eligible and underwent 212 
randomisation from October 14 2015 through July 14 2017 (34 to the vorapaxar group and 213 
31 to the placebo group) at five centres in Australia and two in the United States. Reasons 214 
for screening failure were primarily related to d-dimer levels of <200ng/ml (Fig 1).  One 215 
participant assigned to vorapaxar was lost to follow up immediately after randomisation 216 
prior to receiving any study drug, leaving modified intentional to treat (mITT) groups of 31 in 217 
the placebo arm and 33 in the vorapaxar arm. One participant in the placebo group 218 
withdrew consent at week 4. Thirty participants in the placebo arm and 33 in the vorapaxar 219 
arm reached the end of the study at week 18. 220 
 221 
Baseline demographic and clinical characteristics of the two trial groups were balanced 222 
(Table 1). Participants were primarily (59 of 64, 91%) male, had a median age of 52 years, 223 
and had a baseline risk of CVD within 10 years of 11·4% using a Framingham Heart Study 224 
calculator.  Participants had been diagnosed with HIV infection for a median of 12·5 years. 225 
Participants had controlled HIV RNA and an average CD4+ T cell count of 643 cells per µL. 226 
The most common current ART regimen was two N(t)RTI in combination with either 227 
dolutegravir or raltegravir (55 of 64, 86%), with the remaining participants on two NRTIs in 228 
combination with rilpivirine. The trial successfully recruited participants at risk of future 229 
adverse outcomes based on the median d-dimer concentration (ng/mL) at baseline of 230 
421·9ng/mL. 231 
 232 
Twelve weeks treatment with vorapaxar did not reduce levels of d-dimer, which were 233 
essentially unchanged throughout the trial (Fig 2A). For the primary endpoint calculation, 234 
there was no significant change in log10 d-dimer from baseline to the average level at 8 and 235 
12 weeks after treatment with vorapaxar compared to placebo (-0·02 log10 ng/mL, 95% CI -236 
0·10 to 0·05, p = 0·56 using a regression model adjusted for baseline d-dimer level, Table 2). 237 
The mean % change in d-dimer from baseline to the average of weeks 8 and 12 was -10·8% 238 
and -8·5% for vorapaxar and placebo respectively. There was no difference in d-dimer levels 239 
after either 8 weeks or 12 weeks when analysed separately and there was no rise in d-dimer 240 
between 12 and 18 weeks after vorapaxar was ceased (Table 2). There was no significant 241 
difference in the proportion of subjects in each group that achieved a low d-dimer level of 242 
<165ng/mL at week 12 (2/30 in placebo group vs 1/33 of vorapaxar group, p = 0·60). 243 
 244 
Key secondary outcomes measured levels of inflammation and immune activation. 245 
Vorapaxar treatment had no significant impact on levels on plasma hs-CRP or IL-6 during the 246 
study (Figs 2B, C, Table 2). The change in hs-CRP from baseline to the average level 8 and 12 247 
weeks after treatment with vorapaxar compared to placebo was -0·02 log10 ng/mL, 95% CI -248 
0·20 to 0·24, p = 0.84. The change in IL-6 from baseline to the average level 8 and 12 weeks 249 
after treatment with vorapaxar compared to placebo was -0·08 log10 ng/mL, 95% CI -0·06 to 250 
0·22, p = 0·29. Additional exploratory outcomes were studied to further probe any effect of 251 
vorapaxar. Soluble plasma CD14 and CD163 levels, markers of inflammation/microbial 252 
translocation and monocyte activation respectively, were also not changed by vorapaxar 253 
treatment (Appendix page 6). 254 
 255 
Vorapaxar is a PAR-1 antagonist and a rationale for studying vorapaxar in the context of HIV 256 
was the observation that surface PAR-1 levels are elevated on CD4+ and CD8+ T cells in 257 
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treated HIV infection.14 A subset of 39 participants (19 placebo, 20 vorapaxar) in this study 258 
had flow cytometric analysis of PAR-1 levels on CD4+ and CD8+ T cells on fresh blood 259 
samples. These 39 participants were selected based on being recruited at sites in Australia 260 
with ready access to the flow cytometry assay. PAR-1 expression on the total populations of 261 
CD4+ or CD8+ T cells was not changed by vorapaxar treatment (Appendix page 6). 262 
 263 
Vorapaxar was generally well tolerated with only one participant ceasing vorapaxar because 264 
of an adverse event. Since vorapaxar is an anticoagulant we were particularly interested in 265 
bleeding events. There were 25 bleeding events (13 in placebo, 12 in vorapaxar arms) in 18 266 
subjects. Most (23 events) were mild such as easy bruising or bleeding at the venepuncture 267 
site (BARC 1 grade) with no treatment required. One event (in a participant taking 268 
vorapaxar) was graded as moderate (BARC 2 grade); this was related to a cut from a kitchen 269 
instrument and the subject continued vorapaxar. One event (in a participant taking 270 
vorapaxar) was graded as severe (BARC 3 grade); this was related to a spinal hematoma 271 
developing after an emergency operation for spinal canal stenosis which required surgical 272 
treatment and the participant ceased vorapaxar. 273 
 274 
Vorapaxar had no adverse effect on control of HIV viremia or maintenance of CD4 T cells. A 275 
plasma HIV RNA level of <50 copies per mL was maintained at week 18 in 29/30 in the 276 
placebo arm and 31/33 participants in the vorapaxar arm (p = 0·40). There was no 277 
significant difference in total CD4+ or CD8+ T cell levels between the placebo and vorapaxar 278 
arms during the course of the trial (Appendix page 7). 279 
 280 
There were five protocol defined serious adverse events requiring hospitalisation for more 281 
than 24 hours, two in the placebo arm (pneumonia and colitis) and three in the vorapaxar 282 
arm (spinal canal stenosis requiring surgery, a spinal canal hematoma after surgery in the 283 
same subject, and gout). No subject experienced a serious non-AIDS related event, AIDS, 284 
pregnancy or death. There was a total of 161 adverse events, 84 in the placebo arm and 77 285 
in the vorapaxar arm. There was no difference in the proportion of participants in each arm 286 
experiencing adverse events of any grade (Table 3) and no individual adverse event was 287 
markedly more common in one group (Appendix pages 8-10). No standard laboratory 288 
measures were different between the vorapaxar and placebo groups (data not shown).  289 
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Discussion 290 
 291 
We found vorapaxar was safe in people with well treated HIV infection but did not influence 292 
d-dimer levels nor a series of other inflammatory biomarkers associated with adverse 293 
outcomes. Our multisite double-blind randomised placebo-controlled study was powered to 294 
detect a clinically meaningful change in d-dimer levels, however no effect was observed 295 
across a series of time points during the trial and there was no rebound change after 296 
vorapaxar was ceased.   297 
 298 
The participants studied were at high risk of future cardiovascular events, with median 299 
11·4% 10-year cardiovascular disease risk. The high baseline levels of d-dimer in this 300 
recruited cohort suggest that their cardiovascular risk was even higher than that calculated 301 
by standard algorithms.4 The lack of effect of vorapaxar on biomarkers associated with 302 
cardiovascular risk emphasises the importance of standard cardiovascular risk reduction 303 
measures (including reducing cholesterol, controlling hypertension, stopping smoking) in 304 
this high-risk group. Our study excluded subjects with known cardiovascular disease. We 305 
cannot exclude that vorapaxar may have influenced d-dimer in subjects with known 306 
cardiovascular disease. However, we note that vorapaxar is already licensed for secondary 307 
cardiovascular disease prophylaxis. Further, a post hoc subgroup analysis (Appendix page 308 
11) did not show evidence of d-dimer changes is subjects with high cardiovascular disease 309 
risk. 310 
 311 
We studied vorapaxar since it acts via PAR-1 and this molecule was shown to be 312 
upregulated on T cells in the setting of HIV infection.14 The effect of vorapaxar on PAR-1 313 
expression on T cell subsets was not known prior to this study. We found no effect of 314 
vorapaxar on PAR-1 expression levels in T cells in the subset of 39 subjects where we 315 
studied this repeatedly on fresh blood samples. This suggests PAR-1 levels on T cells is not 316 
central to d-dimer elevations, at least in the context of HIV infection. We did not study PAR-317 
1 levels on platelets which may have been influenced by vorapaxar. Better targets 318 
susceptible to pharmacological interventions along the pathway of d-dimer and IL-6 319 
production and cardiovascular disease are needed. 320 
 321 
Vorapaxar had an acceptable safety profile in this HIV infected subject group. Two 322 
participants taking vorapaxar had significant bleeding episodes provoked by injury (one 323 
after a cut with a kitchen appliance and one after emergency back surgery). Future clinical 324 
trials of anticoagulant therapies in HIV infection are justified given the high rates of 325 
cardiovascular disease and expected safety profile of this level of anticoagulation in this 326 
subject group. 327 
 328 
We acknowledge several limitations of our study. We did not use a loading dose of 329 
vorapaxar as some cardiovascular studies have done19, but we observed no trend over time 330 
in d-dimer changes.  The dose studied, 2·5mg daily, is a relatively safe dose used in current 331 
practice for secondary prophylaxis.18 Although larger doses for a longer duration could have 332 
been studied, this would have placed subjects at a higher risk of bleeding complications. Our 333 
use of biomarkers as primary and secondary endpoints may miss biologic effects with the 334 
potential for clinical importance, but is much more efficient than devoting the resources for 335 
a clinical endpoint study at this stage of investigation. The size of our study also means we 336 
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cannot exclude a modest effect of vorapaxar on d-dimer levels. In our study we saw an 8·5% 337 
reduction in mean week 8–12 d-dimer in the placebo arm, and a 10·8% reduction in the 338 
vorapaxar arm. In formal adjusted analyses this corresponded to a difference in log10 d-339 
dimer of -0·2 (95% CI -0·10 to 0·05). The 95% confidence limit for percent reduction in week 340 
8–12 d-dimer level, given our sample size, rules out a reduction in d-dimer in the vorapaxar 341 
arm to a magnitude greater than 27%. This is much smaller than the 45% reduction in d-342 
dimer as a marker endpoint that our study was powered to detect. We reasoned that a 343 
large effect on this marker would be required to justify future larger studies.4 Since we 344 
found no significant effect on d-dimer or the other multiple surrogate markers studied, even 345 
those at high risk of future cardiovascular disease, we believe clinical endpoint trials with 346 
vorapaxar are not justified in this subject group. 347 
 348 
In conclusion, vorapaxar had no significant effect on d-dimer or markers of inflammation in 349 
the 64 people we studied with treated HIV infection at high risk for future cardiovascular 350 
disease. Improved therapies and targets are needed to reduce cardiovascular disease in this 351 
vulnerable population.  352 
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Figure legends 385 
 386 
Figure 1. Subject disposition. Diagram illustrating subject disposition. The modified 387 
intention to treat group (placebo 31, vorapaxar 34) excluded the one subject randomised to 388 
vorapaxar who was lost to follow up before receiving any study drug. 389 
 390 
Figure 2. d-dimer, hs-CRP and IL-6 levels during the trial. Box and whiskers plots show 391 
median (line), interquartile range (box) and whiskers (defined as UQ+1·5xIQR and LQ-392 
1·5xIQR) for the two groups (vorapaxar grey, placebo black boxes) during the trial. Potential 393 
outliers are not shown. Vorapaxar or placebo was given for weeks 0–12 and then stopped. 394 
A. Plasma d-dimer (ng/mL), B. Plasma hs-CRP (µg/mL), C. plasma IL-6 (pg/mL).  395 
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Figure 1: Patient disposition 
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Figure 2: d-dimer, hs-CRP and IL-6 levels during trial
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Figure 2 Legend: d-dimer, hs-CRP and IL-6 levels during trial. Box and whiskers plots show median 
(line), interquartile range (box) and whiskers (defined as UQ+1.5xIQR and LQ-1.5xIQR)  for the 2 
groups (vorapaxar grey, placebo black boxes) during the trial. Potential outliers are not shown. 
Vorapaxar or placebo was given for weeks 0-12 and then stopped. A. Plasma d-dimer (ng/mL), B. 
Plasma hs-CRP (µg/mL), C. plasma IL-6 (pg/mL).
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Table 1: Baseline characteristics 
 
  placebo (n=31) vorapaxar (n=33) total (n=64) 
Age (years) 52 (48–60)* 52·5 (48–58) 52 (48–60) 
Sex (male) 28 (90·3%) 31 (91·2%) 59 (90·8%) 
Total cholesterol (mmol/L) 4·7 (3·9–5·4) 4·6 (4–5·5) 4·7 (4–5·4) 
HDL (mmol/L) 1·3 (0·9–1·6) 1·2 (1–1·4) 1·2 (1–1·5) 
Systolic blood pressure 127 (120–136) 125 (115–133) 126·5 (117·5–135) 
Diastolic blood pressure 80 (70–86) 77 (70–85) 78·5 (70–85·5) 
Current smoker (n[%]) 9 (29%) 9 (27·3%) 18 (28·1%) 
Framingham heart score: 10 year CVD risk %† 12·1 (8·3–19·4) 10·6 (7·3–21·1) 11·4 (7·9–19·8) 
d-dimer (ng/mL) 391·6 (302·3–813·7) 432·5 (298·0–531·1) 421·9 (299·0–687·6) 
hs-CRP (µg/mL) 1·97 (0·61, 4·81) 1·53 (0·50, 3·01) 1·58 (0·50, 3·86) 
IL-6 (pg/mL) 0·99 (0·69, 1·54) 0·93 (0·61, 1·39) 0·94 (0·62, 1·52) 
Estimated duration of HIV infection (years) 12·2 (8·6, 22·4) 12·8 (9·2, 24·3) 12·5 (8·8, 23·2) 
Plasma HIV RNA (copies/mL)  20 (20–48) 20 (20–48) 20 (20–48) 
CD4+ T-cells/mm
3
  698 (490–869) 639 (504–768) 642·5 (497–828·5) 
Time on current ART (years) 2 (0·7–4) 1·3 (0·7–3) 1·5 (0·7–3·9) 
ART regimens:     
   2 x N(t)RTI + dolutegravir or raltegravir (n[%]) 28 (90%) 27 (82%) 55 (86%) 
   2 x N(t)RTI + rilvipirine (n[%]) 3 (10%) 6 (18%) 9 (14%) 
HCV RNA positive/HCV seropositive (n[%]) 0/3 (10%) 0/5 (15%) 0/8 (12%) 
 
*All values are median (IQR) based on modified intention to treat group unless otherwise noted. 
† As calculated by reference: D’Agnostino RB et al, General cardiovascular risk profile for use in primary care: the 
Framingham Heart Study. Circulation 2008;117:743-53  
Tables1-3
Table 2. Mean change of d-dimer, IL-6 and hs-CRP  
 
 
* study primary endpoint 
† Linear regression for change (log10) modelled against treatment and baseline outcome 
variable.   
Endpoint Mean % [95%CI] change  
Log10 transformed 
data 
 
 placebo vorapaxar 
Difference 
between treatment 
groups† 
p-value 
Baseline to average 
of week 8-12 
 *d-dimer (ng/mL) 
 IL-6 (pg/mL) 
 hs-CRP (µg/mL) 
 
 
-8·5 [-18·4, 2·5] 
-11·6 [-29·1, 10·3] 
-15·7 [-40·9, 20·2] 
 
 
-10·8 [-23·1, 3·4] 
12·6 [-15·6, 50·4] 
-0·02 [-41·3, 70·2] 
 
 
-0·02 [-0·10, 0·05] 
0·08 [-0·06, 0·22] 
0·02 [-0·20, 0·24] 
 
 
0·56 
0·25 
0·84 
Baseline to week 8 
 d-dimer (ng/mL) 
 IL-6 (pg/mL) 
 hs-CRP (µg/m/L) 
 
-10·7 [-19·5, 2·0] 
-14·3 [-33·4, 10·2] 
-14·2 [-41·9, 26·9] 
 
-12·5 [-25·0, 2·1] 
-1·1 [-27·2, 34·4] 
-0·5 [-44·8, 79·4] 
 
-0·03 [-0·10, 0·05] 
0·04 [-0·11, 0·19] 
0·02 [-0·24, 0·27] 
 
0·52 
0·63 
0·91 
Baseline to week 12 
 d-dimer (ng/mL) 
 IL-6 (pg/mL) 
 hs-CRP (µg/mL) 
 
-8·8 [-19·4, 3·2] 
-13·3 [-29·6, 6·9] 
-28·2 [-50·5, 4·2] 
 
-10·2 [-22·9, 4·5] 
10·4 [-16·0, 45·1] 
-24·3 [-50·9, 16·5] 
 
-0·02 [-0·09, 0·06] 
0·08 [-0·05, 0·21] 
-0·02 [-0·21, 0·16] 
 
0·64 
0·22 
0·79 
Week 12 to week 18 
 d-dimer (ng/mL) 
 IL-6 (pg/mL) 
 hs-CRP (µg/mL) 
 
8·0 [-6·9, 25·2] 
-8·2 [-21·5, 7·5] 
11·6 [-14·4, 45·3] 
 
8·9 [-5·0, 24·9] 
-1·9 [-29·1, 35·7] 
24·6 [-14·7, 82·1] 
 
0·003 [-0·08, 0·09] 
0·03 [-0·12, 0·18] 
0·07 [-0·13, 0·25] 
 
0·95 
0·70 
0·53 
Table 3. Numbers of Adverse Events including Bleeding events^ 
 
 Grade 1 
(mild) 
Grade 2 
(moderate) 
Grade 3 
(severe) 
Grade 4 
(potentially 
life 
threatening) 
Total 
Adverse 
events† 
BARC 
bleeding 
events 
Placebo  
n events, 
n subjects#, % 
 
52 
14 , 45.2% 
 
16  
10, 32.3% 
 
3 
2, 6·5% 
 
0 
0, 0·0% 
 
84* 
31 
 
13  
10, 32·3% 
       
Vorapaxar  
n events, 
n subjects#, % 
 
37 
13, 39·4% 
 
24 
12, 36.4% 
 
3 
2, 6·1% 
 
1  
1, 3.0% 
 
77 
33 
 
12  
8, 24·2% 
 
* Fisher’s exact test for (a) difference in proportion of subjects having an adverse event Grade 1-4 
by treatment arm (P=0·99) and (b) difference in proportion of subjects having any bleeding event 
by treatment arm (P= 0·58). 
 
# Subjects were classified according to the highest severity adverse event; any BARC event 
(yes/no) was compared.  There were n=3 subjects (placebo) and n=5 (vorapaxar) with no adverse 
event. 
 
^Defined through the NH Division of AIDS (DAIDS) Table for Grading the Severity of Adult 
and Paediatric Adverse Events (Version 2.0, November 2014) and the Bleeding Academic 
Research Consortium (BARC) Definitions for Bleeding Events (2011) 
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Figure	S1.	Detection	of	protease-activated	receptor	1	(PAR-1)	on	the	surface	of	human	CD4+	and	CD8+	T-
cells	using	multi-parameter	flow-cytometry.	CD4+	and	CD8+	T-cells	were	first	defined	(as	'not	platelet')	by	
high	side-scatter	area	(SSC-A)	to	exclude	platelet	status,	when	combined	with	cell-surface	expression	of	
CD42b	(platelet	glycoprotein	Ib).	Not-platelet	small	lymphocytes	were	defined	by	SSC-A	and	forward-scatter	
area	(FSC-A)	to	exclude	monocytes	and	granulocytes.	CD3+	lymphocytes	were	selected	by	an	interval	gate	
and	then	divided	by	cell-surface	expression	of	proteins	CD4	or	CD8.	PAR-1	cell-surface	expression	that	was	
exclusive	to	T-cells	were	via	selection	of	side-scatter	width	low	(SSC-W	low)	CD4+	or	CD8+	T-cells,	and	further	
selection	of	pure	T-cells	through	a	CD42b	(negative)	gate,	to	limit	detection	of	PAR-1	expressed	on	the	
surface	of	platelets	that	were	non-covalently	conjugated	to	the	T-cell	wall	at	the	time	of	analysis.	
Standardised	PAR-1	surface	expression	on	CD4+	and	CD8+	T-cells	were	set	using	a	full	antibody-cocktail	in	the	
presence	or	in	the	absence	of	PAR-1,	referred	to	as	a	fluorescence	minus-one	(FMO)	control	tube.		PAR-1+	
CD4+	or	CD8+	T-cell	frequencies	were	collected	and	entered	into	the	ADVICE	clinical	trial	database	minus	the	
frequency	detected	in	the	FMO	control	tube.	
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Figure	S2.	Inflammation	and	PAR-1	levels	during	the	trial.	Box	and	whiskers	plots	show	median	(line),	
interquartile	range	(box)	and	whiskers	(defined	as	UQ+1·5xIQR	and	LQ-1·5xIQR)	for	the	two	groups	
(vorapaxar	grey,	placebo	black	boxes)	during	the	trial.	Potential	outliers	are	not	shown.	Vorapaxar	or	placebo	
was	given	for	weeks	0–12	and	then	stopped.	A.	plasma	soluble	CD14	(µg/mL),	B.	plasma	soluble	CD163	
(ng/mL),	C.	Percentage	of	blood	CD4+	T	cells	expressing	PAR-1,	D.	Percentage	of	blood	CD8+	T	cells	
expressing	PAR-1.	The	C.	and	D.,	analyses	were	restricted	to	39	subjects	in	total.	The	gating	strategy	to	define	
PAR-1	expressing	T	cells	is	shown	in	Figure	S2.	
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Figure	S3.	CD4	and	CD8	T	cell	levels	during	the	trial.	Box	and	whiskers	plots	show	median	(line),	interquartile	
range	(box)	and	whiskers	(defined	as	UQ+1·5xIQR	and	LQ-1·5xIQR)	for	the	two	groups	(vorapaxar	grey,	
placebo	black	boxes)	during	the	trial.	Potential	outliers	are	not	shown.	Vorapaxar	or	placebo	was	given	for	
weeks	0–12	and	then	stopped.	A.	CD4	T	cells	levels	in	blood	(number/mm3	of	blood).	A.	CD8	T	cells	levels	in	
blood	(number/mm3	of	blood).	
	
	 	
	 	 8 
Table	S1:	All	adverse	Events	by	treatment	group	
	
Adverse	Event	–	MedDRA	20.0	
Preferred	Term	
Placebo	
n	
Vorapaxar	
n	
Upper	respiratory	tract	infection	 8	 4	
Epistaxis	 2	 6	
Headache	 2	 4	
Laceration	 3	 3	
Gout		
	
5	
Contusion	 3	 1	
Back	pain	 2	 1	
Chest	pain	 1	 2	
Colitis	 3	
	Dyspepsia	 1	 2	
Palpitations	 1	 2	
Peripheral	swelling	 2	 1	
Cough	 1	 1	
Dizziness	 2	
	Dry	mouth	 1	 1	
Hypoaesthesia	 1	 1	
Oedema	peripheral	 1	 1	
Pain	in	extremity	 2	
	Paraesthesia	 2	
	Viral	infection	 1	 1	
Vomiting	 2	
	Seasonal	allergy	 1	 1	
Cerumen	impaction	 1	 1	
Respiratory	tract	congestion	 1	 1	
Respiratory	tract	infection	viral	 1	 1	
Oral	herpes	 1	 1	
Abdominal	distension	 1	
	Acne	 1	
	Allergy	to	animal	 1	
	Anal	chlamydia	infection	 1	
	Arthralgia	
	
1	
Bacterial	vaginosis	 1	
	Bursitis	
	
1	
Cellulitis	staphylococcal	
	
1	
Chills	 1	
	Chronic	obstructive	pulmonary	disease	 1	
Dermal	cyst	
	
1	
Dermatitis	
	
1	
Diarrhoea	
	
1	
	 	 9 
Dyshydrotic	Eczema	
	
1	
Dyspnoea	 1	
	Ear	Pain	
	
1	
Eczema	 1	
	Eye	infection	 1	
	Eye	irritation	 1	
	Fatigue	 1	
	Flatulance	 1	
	Gastrooesophageal	reflux	disease	
	
1	
Gastroenteritis	 1	
	Gastroenteritis	viral	
	
1	
Genital	herpes	
	
1	
Gingival	bleeding	 1	
	Gonorrhoea	
	
1	
Haematuria	 1	
	Haemoptysis	 1	
	Hordeolum	 1	
	Hyperkeratosis	
	
1	
Increased	tendency	to	bruise	
	
1	
Influenza	like	illness	 1	
	Ingrowing	nail	 1	
	Injection	site	haemorrhage	 1	
	Irritability	 1	
	Lethargy	
	
1	
Lumbar	spinal	stenosis	
	
1	
Melaena	 1	
	Mouth	ulceration	 1	
	Muscle	spasms	
	
1	
Musculoskeletal	pain	
	
1	
Nasopharyngitis	
	
1	
Nausea	 1	
	Neck	pain	
	
1	
Neurodermatitis	
	
1	
Oral	pain	
	
1	
Peroneal	nerve	palsy	 1	
	Petaechaie	both	anterior	shoulders	 1	
	Pleurisy	 1	
	Pneumonia	 1	
	Prostatitis	
	
1	
Pruitis	 1	
	Groin	Itch	
	
1	
Rash	 1	
	Rash	pustular	 1	
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Rhinitis	 1	
	Scab	
	
1	
Sinus	Congestion	
	
1	
Tinnitus	 1	
	Tonsilitis	
	
1	
Umbilical	Hernia	Repair	
	
1	
Urticaria	 1	
	Puncture	site	haemorrhage	
	
1	
Pruritus	generalised	
	
1	
Nonalcoholic	steatohepatitis	 1	
	Staphylococcal	infection	
	
1	
Hot	flush	 1	
	Chlamydial	infection	 1	
	Syphilis	
	
1	
Post	procedural	haematoma	
	
1	
Vessel	puncture	site	bruise	
	
1	
Skin	mass	
	
1	
Anal	pruritus	 1	
	Total	 84	 77	
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Table	S2.	Mean	change	of	d-dimer	based	on	CVD	risk		
	
	
*FHS	=	Framingham	heart	score	(Reference:	D’Agnostino	RB	et	al,	General	cardiovascular	risk	profile	for	use	
in	primary	care:	the	Framingham	Heart	Study.	Circulation	2008;117:743-53)	
†	Linear	regression	for	change	(log10)	modelled	against	treatment	and	baseline	outcome	variable.	
	
	 	
Baseline	d-dimer	to	
average	of	week	8-12	
	
Mean	%	[95%CI]	change		 Log10	transformed	data	 	
	 placebo	 vorapaxar	
Difference	
between	treatment	
groups†	
p-value	
Total	group	(median	
FHS*	10	year	risk	=	11.4)	
-8·5	[-18·4,	2·5]	
-11.43	[-27.19,	7.77]	
-5.14	[-16.50,	7.80]	
-10·8	[-23·1,	3·4]	
-6.22	[-19.78,	9.62]	
-14.22	[-33.71,	11.05]	
-0·02	[-0·10,	0·05]	
0.01	[-0.09,	0.10]	
	
	
-0.04	[-0.15,	0.07]	
0·56	
0.89	
0.49	
Higher	than	median	CVD	
risk	(median	FHS	10	year	
risk	=	19.8)	
Lower	than	median	CVD	
risk	(median	FHS	10	year	
risk	=	7.9)	
